Humira Biosimilar Settlement Could Be Model For Other Disputes
Agreement with AbbVie allows Amgen to launch its Humira biosimilar in Europe in 2018 and in the US in 2023; it may be akin to generic settlements but it is uncertain if other sponsors will get similar deals.
You may also be interested in...
AbbVie seeks injunction against Boehringer Ingelheim's Cyltezo claiming infringement of 74 patents, 8 of which are in the initial round of litigation; as of Aug. 2, BI had not given 180-day launch notice.
Patent Trial and Appeal Board rules for Coherus in its challenge of Humira patents and takes up review of Cialis patent. US high court to consider constitutionality of inter partes review proceeding.
'Amgen is speaking out of both sides of its mouth', AbbVie contends, promising suit on dozens more patents.